Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. New York
    4. ›
  4. 12210
    5. ›
  5. LUCERNA INC.

LUCERNA INC.

Company claim

Is this your business?

Get access!

Company Details

Name: LUCERNA INC.
Jurisdiction: New York
Legal type: DOMESTIC BUSINESS CORPORATION
Status: Active
Date of registration: 05 Mar 2010 (15 years ago)
Entity Number: 3920137
ZIP code: 12210
County: New York
Place of Formation: New York
Address: ONE COMMERCE PLAZA, 99 WASHINGTON AVE. SUITE 805A, ALBANY, NY, United States, 12210
Principal Address: 760 PARKSIDE AVENUE, SUITE 327C, BROOKLYN, NY, United States, 11226

Shares Details

Shares issued 10000000

Share Par Value 0.001

Type PAR VALUE

DOS Process Agent

Name Role Address
INCORP SERVICES, INC. DOS Process Agent ONE COMMERCE PLAZA, 99 WASHINGTON AVE. SUITE 805A, ALBANY, NY, United States, 12210

Agent

Name Role Address
INCORP SERVICES, INC. Agent ONE COMMERCE PLAZA, 99 WASHINGTON AVE. SUITE 805A, ALBANY, NY, 12210

Chief Executive Officer

Name Role Address
KAREN WU Chief Executive Officer 760 PARKSIDE AVENUE, SUITE 327C, BROOKLYN, NY, United States, 11226

U.S. Small Business Administration Profile

Phone Number:
646-504-5697
E-mail Address:
karen.wu@lucernatechnologies.com
Contact Person:
KAREN WU
Ownership and Self-Certifications:
Asian Pacific American, Other Minority Owned, Self-Certified Small Disadvantaged Business, Women-Owned Small Business, Woman Owned
User ID:
P1198045

Unique Entity ID

CAGE Code:
5XRS8
UEI Expiration Date:
2021-01-02

Business Information

Activation Date:
2020-01-03
Initial Registration Date:
2010-03-19

Commercial and government entity program

CAGE number:
5XRS8
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2025-06-24
CAGE Expiration:
2030-06-24
SAM Expiration:
2026-06-19

Contact Information

POC:
KAREN WU

Form 5500 Series

Employer Identification Number (EIN):
272119673
Plan Year:
2015
Number Of Participants:
2
Sponsors Telephone Number:
6467924724
File:
View File
Plan Year:
2014
Number Of Participants:
1
Sponsors Telephone Number:
6465045697
File:
View File
Plan Year:
2014
Number Of Participants:
1
Sponsors Telephone Number:
6465045697
Plan Year:
2013
Number Of Participants:
1
Sponsors Telephone Number:
6467924724
File:
View File

History

Start date End date Type Value
2024-04-10 2024-04-10 Address 760 PARKSIDE AVENUE, SUITE 327C, BROOKLYN, NY, 11226, USA (Type of address: Chief Executive Officer)
2020-03-02 2024-04-10 Address 760 PARKSIDE AVENUE, SUITE 327C, BROOKLYN, NY, 11226, USA (Type of address: Chief Executive Officer)
2018-03-06 2020-03-02 Address 760 PARKSIDE AVENUE, SUITE 327B, BROOKLYN, NY, 11226, USA (Type of address: Principal Executive Office)
2018-03-06 2020-03-02 Address 760 PARKSIDE AVENUE, SUITE 327B, BROOKLYN, NY, 11226, USA (Type of address: Chief Executive Officer)
2012-05-02 2018-03-06 Address 3960 BROADWAY, SUITE 330E, NEW YORK, NY, 10032, USA (Type of address: Chief Executive Officer)

Filings

Filing Number Date Filed Type Effective Date
250508003850 2025-05-07 CERTIFICATE OF MERGER 2025-05-07
240410004060 2024-04-10 BIENNIAL STATEMENT 2024-04-10
200302060226 2020-03-02 BIENNIAL STATEMENT 2020-03-01
180306006662 2018-03-06 BIENNIAL STATEMENT 2018-03-01
160302006576 2016-03-02 BIENNIAL STATEMENT 2016-03-01

USAspending Awards / Contracts

Procurement Instrument Identifier:
75N91019C00046
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DEFINITIVE CONTRACT
Action Obligation:
1480983.00
Base And Exercised Options Value:
1480983.00
Base And All Options Value:
1480983.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2019-09-16
Description:
TOPIC 356: FLUOROGENIC ASSAY PLATFORM FOR CIRCULAR RNA DETECTION
Naics Code:
541715: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
Product Or Service Code:
AN13: R&D- MEDICAL: BIOMEDICAL (ADVANCED DEVELOPMENT)
Procurement Instrument Identifier:
HHSN261201700044C
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DEFINITIVE CONTRACT
Action Obligation:
249642.00
Base And Exercised Options Value:
249642.00
Base And All Options Value:
249642.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2017-09-18
Description:
IGF::OT::IGF SBIR PHASE I TOPIC 356 FLOUROGENIC ASSAY PLATFORM FOR CIRCULAR RNA DETECTION POP 9/18/2017 - 6/18/2018.
Naics Code:
541712: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)
Product Or Service Code:
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

USAspending Awards / Financial Assistance

Date:
2024-07-29
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
TARGETED RNA DEGRADATION ASSAY FOR NEW ANTIVIRAL DRUG DISCOVERY - PROJECT SUMMARY THERE ARE CURRENTLY NO EFFECTIVE VACCINES OR ANTIVIRAL DRUGS FOR MOST OF THE VIRAL DISEASES AFFLICTING HUMAN. DEVELOPMENT OF NEW THERAPY IS CHALLENGING AND EXPENSIVE, AND OFTEN COMPLICATED BY DRUG RESISTANCE. IT IS NOW KNOWN THAT VIRAL TRANSCRIPTS CONTAIN MANY HIGHLY STRUCTURED RNA ELEMENTS IN BOTH THE CODING AND NONCODING REGIONS, AND THEY PLAY KEY ROLES IN THE VIRAL LIFE CYCLE. MANY OF THESE ELEMENTS ARE HIGHLY CONSERVED AND, THUS, THEY ARE ATTRACTIVE NEW TARGETS THAT POTENTIALLY HAVE LOWER LIKELIHOODS OF VIRAL RESISTANCE DEVELOPMENT. TARGETED RNA DEGRADATION (TRD) IS AN EMERGING STRATEGY IN RECENT EFFORTS TO FURTHER DISCOVER NEW ANTIVIRAL SMALL MOLECULES WITH PRIVILEGED SCAFFOLDS AND BETTER RESISTANCE PROFILES. HOWEVER, EARLY-STAGE TRD DRUG DISCOVERY HAS BEEN HINDERED BY CURRENT HIGH-THROUGHPUT SCREENING (HTS) ASSAY TECHNOLOGIES DESIGNED FOR PROTEIN TARGETS. VIRTUALLY ALL CELL-BASED DRUG SCREENS USED MINIGENE REPORTERS THAT RELY ON LUCIFERASE OR FLUORESCENT PROTEIN SIGNALS FOR ASSAY READ-OUT. MINIGENE REPORTER DESIGN IS STRAIGHTFORWARD BUT MINIGENE REPORTER REQUIRES MRNA EXPORT TO THE CYTOSOL AND PROTEIN TRANSLATION. THIS SIGNIFICANTLY INCREASES THE RATE OF FALSE HITS PER SCREEN SINCE COMPOUNDS THAT INHIBIT GLOBAL PROTEIN TRANSLATION MACHINERY OR RNA EXPORT WILL ALSO IMPACT REPORTER READ-OUT. ASSAYS THAT MONITOR ENDOGENOUS RNA LEVELS ARE LOW-THROUGHPUT OR TIME-CONSUMING, INVOLVE MULTIPLE STEPS, AND NOT READILY ADAPTABLE FOR HIGH-THROUGHPUT SM SCREENING. THUS, THERE IS AN UNMET NEED FOR A NEW CELL-BASED HTS ASSAY PLATFORM THAT MONITORS TARGET RNA TURNOVER DIRECTLY, REFLECTS REAL-TIME RNA DYNAMICS, AND COMPATIBLE FOR DIFFERENT TYPES OF RNA AND DIFFERENT TRD APPROACHES. FOR PROOF-OF-CONCEPT, THIS PROJECT AIMS TO DEVELOP HTS-COMPATIBLE REPORTERS THAT CAN MEASURE DRUG- INDUCED CHANGES OF RNA LEVELS OF DENGUE AND INFLUENZA VIRUSES, TWO GLOBAL PATHOGENS WITH DIFFERENT GENOMIC STRUCTURES AND LIFE CYCLES. THE ULTIMATE PRODUCT OF THIS SBIR PROJECT WILL BE A CELL-BASED HTS ASSAY PLATFORM THAT CAN ACCELERATE THE EARLY-STAGE DISCOVERY OF TRD DRUGS TOWARD PREVIOUSLY INTRACTABLE VIRAL DISEASES.
Obligated Amount:
300000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-11-17
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
CELL-BASED RNA DEGRADATION ASSAY FOR C9ALS/FTD DRUG DISCOVERY - PROJECT SUMMARY TO OVERCOME THE “UNDRUGGABLE” PROTEIN PROBLEM, RESEARCHERS HAVE TURN TO DRUGGING MRNAS THAT TRANSLATE INTO THESE UNDRUGGABLE PROTEINS OR NON-CODING RNAS THAT REGULATE THE BIOGENESIS OF THESE PROTEINS. AVENUES OF CONTROLLING RNA DEGRADATION INCLUDE INDUCED PROXIMITY DEGRADATION OR SPLICING MODULATED NONSENSE-MEDIATED DECAY (NMD). INDUCED PROXIMITY DEGRADATION IS A STRATEGY WHERE A BIFUNCTIONAL DRUG BINDS A TARGET RNA VIA A SMALL MOLECULE (SM) ENTITY ON ONE ARM AND INDUCES SELECTIVE RNA DEGRADATION VIA A RIBONUCLEASE ON THE OTHER ARM. THERAPEUTIC MODULATION OF NMD VIA RNA SPLICING IS ANOTHER STRATEGY TO SELECTIVELY CONTROL RNA DEGRADATION. EARLY-STAGE RNA DEGRADATION DRUG DISCOVERY HAS BEEN HINDERED BY CURRENT HIGH-THROUGHPUT SCREENING (HTS) ASSAY TECHNOLOGIES DESIGNED FOR PROTEIN TARGETS. SPECIFICALLY, CELL-BASED DRUG SCREENS USE MINIGENE REPORTERS THAT RELY ON LUCIFERASE OR FLUORESCENT PROTEIN SIGNALS FOR ASSAY READ-OUT. MINIGENE REPORTER DESIGN IS STRAIGHTFORWARD BUT MINIGENE REPORTER REQUIRES MRNA EXPORT TO THE CYTOSOL AND PROTEIN TRANSLATION. THIS SIGNIFICANTLY INCREASES THE RATE OF FALSE HITS PER SCREEN SINCE COMPOUNDS THAT INHIBIT GLOBAL PROTEIN TRANSLATION MACHINERY OR RNA EXPORT WILL ALSO IMPACT REPORTER READ-OUT. FURTHER, PROTEIN-BASED REPORTERS CANNOT BE USED TO STUDY NUCLEAR RNA OR NON- CODING RNA TURNOVER, AND IN DISEASES WITH NUCLEAR EXPORT DEFECTS. THUS, THERE IS AN UNMET NEED FOR A CELL-BASED HTS ASSAY PLATFORM THAT MONITORS SELECTED RNA TURNOVER DIRECTLY, REFLECTS REAL- TIME RNA DYNAMICS, AND COMPATIBLE FOR DIFFERENT TYPES OF RNA. A PRIME EXAMPLE WHERE A PREVIOUSLY INTRACTABLE DISEASE CAN BE UNLOCKED BY RNA DEGRADING DRUGS IS THE G4C2 HEXANUCLEOTIDE REPEAT EXPANSION IN THE C9ORF72 GENE – THE MOST FREQUENT GENETIC CAUSE OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND FRONTOTEMPORAL DEMENTIA (FTD). IT IS NOW KNOWN THAT THE TOXIC GAIN-OF-FUNCTION FROM THE EXPANDED G4C2 REPEATS INDUCES ALS/FTD PATHOLOGY. ANTISENSE OLIGONUCLEOTIDES (ASOS) DESIGNED TO BIND EITHER THE G4C2 SEQUENCES OR INTRONIC REGIONS DOWNSTREAM OF THE REPEAT SEQUENCES SHOWED REDUCTION IN DISEASE PHENOTYPES IN C9ORF72 MODELS. HOWEVER, ASOS CAN TRIGGER IMMUNE RESPONSES AND SUFFER FROM TISSUE DELIVERY ISSUES. A CELL- BASED ASSAY THAT CAN REPORT EXPANDED TRANSCRIPT TURNOVER TO IDENTIFY EFFECTIVE C9ORF72 RNA GAIN- OF-FUNCTION SM INHIBITORS WILL HAVE HIGH COMMERCIAL POTENTIAL. THE GOALS OF THIS PHASE I SBIR APPLICATION WILL BE CELL-BASED RNA DEGRADATION REPORTERS FOR VALIDATED RNA TARGETS IN NEURODEGENERATIVE DISEASES. THE RESULTS WILL FORM THE FOUNDATION OF AN HTS ASSAY PLATFORM FOR EARLY-STAGE DISCOVERY SMS THAT MODULATE RNA STABILITY.
Obligated Amount:
392116.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2022-09-21
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
FLUORESCENT IRE SENSOR FOR SYNUCLEINOPATHY DRUG DISCOVERY - ABSTRACT THE GOAL OF THIS PHASE II PROPOSAL IS TO ADVANCE SYNUCLEINOPATHY DISEASE DRUG DISCOVERY BY VALIDATING A HIGH- THROUGHPUT SCREENING (HTS)-READY ASSAY AND ESTABLISH A RNA STRUCTURE SENSOR PLATFORM FOR RNA-TARGETED DRUG DISCOVERY. DEMENTIA WITH LEWY BODIES IS THE SECOND MOST COMMON FORM OF DEGENERATIVE DEMENTIA IN THE ELDERLY POPULATION AFTER ALZHEIMER’S DISEASE; AND IT IS CHARACTERIZED BY ABNORMAL ACCUMULATION OF ALPHA-SYNUCLEIN (SNCA) AGGREGATES. DISEASES FEATURING PATHOGENIC SNCA PROTEINS ARE COLLECTIVELY KNOWN AS SYNUCLEINOPATHIES, WHICH ALSO INCLUDE PARKINSON’S DISEASE, MULTIPLE SYSTEM ATROPHY, AND ALZHEIMER’S DISEASE WITH AMYGDALA RESTRICTED LEWY BODIES. THERE IS CURRENTLY NO DISEASE-MODIFYING CURE AVAILABLE FOR ANY OF THE SYNUCLEINOPATHIES. IT IS KNOWN THAT SNCA GENE DUPLICATION INCREASES SNCA LEVELS AND IS CORRELATED WITH DISEASE PROGRESSION AND SEVERITY, LEADING TO EARLY PARKINSONISM AND DEMENTIA. STUDIES SHOWED REDUCTIONS IN SNCA LEVELS CAN REDUCE AGGREGATION, PREVENT LEWY BODY FORMATION, AND CONFER NEUROPROTECTION. THUS, INHIBITING SNCA EXPRESSION DURING DISEASE PRODROMAL PHASE HAS THE POTENTIAL TO SLOW DISEASE PROGRESSION OR HALT DISEASE ONSET. SNCA TRANSLATION IS CONTROLLED BY AN IRON-RESPONSE ELEMENT (IRE) IN THE 5’UTR OF THE MRNA. TO DEMONSTRATE FEASIBILITY, WE DEVELOPED PROOF-OF-CONCEPT RNA STRUCTURE SENSORS THAT WERE RESPONSIVE TO THE BINDING OF SMALL MOLECULES AND ANTISENSE OLIGONUCLEOTIDES, AND DEMONSTRATED FEASIBILITY FOR HTS USE. TO ACCOMPLISH THE GOAL OF THIS PROPOSAL, WE WILL COMPLETE THE FOLLOWING SPECIFIC AIMS: 1) FINALIZE HTS OPTIMIZATION OF THE SNCA-SPECIFIC RNA SENSOR AND PERFORM A PILOT SCREEN, 2) ESTABLISH THE GENERALIZABILITY OF THE RNA STRUCTURE SENSOR PLATFORM BY DEVELOPING HTS- COMPATIBLE SENSORS TARGETING ANOTHER PATHOGENIC RNA STRUCTURE, 3) DEVELOP A STANDARD OPERATING PROCEDURE FOR THE COMMERCIALIZATION OF CUSTOM RNA SENSOR SERVICES, 4) PERFORM A PRIMARY SCREEN TO IDENTIFY INHIBITORS OF SNCA PROTEIN TRANSLATION. IF SUCCESSFUL, WE WILL HAVE A VALIDATED HTS ASSAY FOR SYNUCLEINOPATHY DRUG DISCOVERY AND A RNA STRUCTURE SENSOR PLATFORM THAT AIMED TO ACCELERATE THE CURRENT PACE IN RNA STRUCTURE-BASED DRUG DISCOVERY AND TO ENABLE MORE RNA-TARGETED DRUG DEVELOPMENT PROGRAMS TARGETING DISEASE-CAUSING RNA STRUCTURES.
Obligated Amount:
1728231.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2020-05-22
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
-80000.00
Total Face Value Of Loan:
0.00
Date:
2020-03-30
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
CELL-BASED ASSAY DIRECTLY MONITORING RNA POLYMERASE I ACTIVITY FOR CANCER DRUG DISCOVERY
Obligated Amount:
223700.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

INCORP SERVICES, INC.

1 OAK RICHLAND LLC 10 JAY MM LLC 10 PAXTON AVENUE, LLC 10-18 47TH AVENUE, LLC 10-27 47TH ROAD, LLC 10414 LIBERTY AVE, INC 107 ROBERTSON LLC 10NORTHEAST II LLC TAHT LLC 111B FAMILY LLC

Related by address

ONE COMMERCE PLAZA, 99 WASHINGTON AVE. SUITE 805A, ALBANY, NY, United States, 12210

232 CONSTRUCTION LLC ADVANCED SHIPPING TECHNOLOGIES, INC. ARC MANAGEMENT GROUP, LLC B2B CUSTOM LEADS LLC BAKERY GROUP LLC CHARLES ESTATE PROPERTIES, LLC DENTAL.NET, LLC ENTRA SOLUTIONS, LLC FANTASTIC FOREST, LLC FASHIONISTAMOVIE LLC

Date of last update: 27 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated